Abstract
Controlled human malaria infection in Kenyan adults: A safe model that could accelerate assessment of novel drugs and vaccines in malaria endemic populations Susanne Hodgson, Elizabeth Juma, Amina Salim, Charles Magiri, Domtila Kimani, Daniel Njenga, Alfred Muia, Andrew Cole, Caroline Ogwang, Peter Billingsley, Eric James, Kim Lee Sim, Thomas Rampling, Adrian Hill, Faith Osier, Simon Draper, Philip Bejon, Stephen Hoffman, Bernhards Ogutu, Kevin Marsh
Highlights
Controlled human malaria infection (CHMI) studies, where healthy volunteers are infected with Plasmodium falciparum have become a vital tool to accelerate vaccine and drug development
A significant correlation was seen between parasite multiplication rate (PMR) and anti-schizont ELISA OD at screening (P = 0.044)
Our study has shown that the PfSPZ Challenge is safe and infectious in malaria endemic populations and could be used to aid early assessment of the efficacy of candidate malaria vaccines and drugs in African populations
Summary
Controlled human malaria infection (CHMI) studies, where healthy volunteers are infected with Plasmodium falciparum have become a vital tool to accelerate vaccine and drug development. As CHMI trials are carried out in a controlled environment, they allow unprecedented, detailed evaluation of parasite growth dynamics and immunological responses to infection. Though commonly performed in malaria-naïve populations, CHMI trials have rarely been performed in malaria endemic regions, despite the advantages of early testing of candidate antimalaria vaccines and drugs in populations where malaria is endemic. Modern CHMI studies have not been used to investigate mechanisms of naturally acquired immunity (NAI) to P. falciparum infection
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call